Press Releases Site - Investor Navigation Corporate Profile Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Analyst Coverage Financial Filings SEC Filings Corporate Governance Documents & Charters Management Team Board of Directors Investor Resources Investor FAQs Investor Email Alerts Contact IR Year None20232022202120202019 Nov 09, 2023 Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Nov 07, 2023 Ikena Oncology to Present at Multiple November 2023 Investor Conferences Sep 05, 2023 Ikena Oncology to Participate in September 2023 Investor Conferences Aug 10, 2023 Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update Aug 07, 2023 Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction May 24, 2023 Ikena Oncology to Participate in Upcoming Investor Conferences May 15, 2023 Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline May 15, 2023 Ikena Oncology Announces $40 Million Underwritten Offering Apr 20, 2023 Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days Apr 17, 2023 Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting Pagination Current page 1 Page 2 Next page next › Last page last » Print Page Email Alerts RSS Feeds
Year None20232022202120202019 Nov 09, 2023 Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Nov 07, 2023 Ikena Oncology to Present at Multiple November 2023 Investor Conferences Sep 05, 2023 Ikena Oncology to Participate in September 2023 Investor Conferences Aug 10, 2023 Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update Aug 07, 2023 Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction May 24, 2023 Ikena Oncology to Participate in Upcoming Investor Conferences May 15, 2023 Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline May 15, 2023 Ikena Oncology Announces $40 Million Underwritten Offering Apr 20, 2023 Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days Apr 17, 2023 Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting Pagination Current page 1 Page 2 Next page next › Last page last »
Nov 09, 2023 Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
May 15, 2023 Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
Apr 17, 2023 Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
